Browse the evidence

Targeting the melanocortin-4 receptor (MC4R) with biased agonists that favor Gq/11 signaling over Gs signaling reduces food intake and adiposity without causing adverse cardiovascular effects like hypertension and tachycardia.

If you have a specific genetic form of obesity linked to MC4R, a drug called setmelanotide may help you lose weight and improve glucose tolerance without raising your blood pressure, unlike some older treatments. This is because it targets the specific receptor pathway that controls appetite without triggering the heart-related side effects.

GLP-1RAs exhibit neuroprotective effects and may improve symptoms in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and cognitive dysfunction associated with type 2 diabetes.

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, GLP-1 receptor agonists like semaglutide can significantly reduce heart failure symptoms and improve physical limitations. Additionally, there is emerging evidence that these medications may offer neuroprotective benefits, potentially slowing cognitive decline in patients with T2DM.

Adipose tissue dysfunction, specifically the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and free fatty acids from visceral fat, drives insulin resistance and beta-cell dysfunction in obesity.

Fat is not just stored energy; it actively sends inflammatory signals that block your body's ability to use insulin. Reducing visceral fat reduces this inflammation, thereby improving insulin sensitivity.

Plasma proteome profiling can identify specific protein panels that correlate with insulin resistance (HOMA-IR) and BMI better than or equal to traditional markers like adiponectin, allowing for the identification of high metabolic burden subgroups.

Current clinical markers may not fully capture metabolic risk. Proteomic profiling can identify specific protein panels that correlate better with insulin resistance and BMI than traditional markers like adiponectin. This suggests that future diagnostic tools may use these panels to more accurately identify individuals with high metabolic burden and tailor interventions accordingly.

In older men, the spatial distance between type II muscle fiber-associated satellite cells (SC) and capillaries is significantly greater than in young men, which may impair SC activation and contribute to age-related muscle atrophy.

As men age, the communication line between muscle stem cells (satellite cells) and blood vessels (capillaries) weakens, specifically in fast-twitch muscle fibers. This physical distance may make it harder for muscles to repair and grow after exercise. To counteract this, older adults should prioritize resistance training, which has been shown to activate satellite cells and potentially improve their proximity to capillaries, supporting muscle maintenance.

Following a single bout of resistance exercise, activated satellite cells (MyoD+) are located significantly closer to capillaries than quiescent satellite cells (MyoD-) in young men, suggesting that proximity to capillaries facilitates SC activation.

Resistance exercise triggers satellite cells to activate, and these activated cells tend to be closer to blood vessels, which likely helps deliver the nutrients and signals they need to repair muscle. This highlights the importance of resistance training for maintaining muscle health, especially as we age.

Premenopausal women exhibit sex-specific fat distribution characterized by preferential subcutaneous adipose tissue (SAT) storage and higher brown adipose tissue (BAT) activity, which provides metabolic protection against visceral obesity and cardiovascular disease compared to men.

If you are a premenopausal woman, your body naturally stores fat in your hips and thighs (subcutaneous) rather than around your organs (visceral), and you likely have more active brown fat for energy burning. This is a biological advantage for metabolic health. Do not equate higher total body fat with higher health risk compared to men; your distribution pattern is protective.

Eight weeks of fish oil supplementation (5 g/day) suppresses anabolic signaling (panPKB, p70S6K1, AMPKa2) in response to resistance exercise and protein ingestion without increasing myofibrillar muscle protein synthesis rates in young, resistance-trained men.

If you are a young, resistance-trained man, taking 5g of fish oil daily for 8 weeks will not increase your muscle protein synthesis rates after working out and eating protein. It actually suppresses key anabolic signaling markers (like p70S6K1) without providing any anabolic benefit. Do not rely on fish oil to boost muscle growth; it may be neutral or even counterproductive to signaling in this specific demographic.

High baseline plasma levels of specific advanced glycation end products (G-H1) and oxidation products (2-AAA) are strongly associated with greater severity of subclinical atherosclerosis (measured by CIMT, CAC, and AAC) over a 10-year follow-up in patients with type 2 diabetes.

For people with type 2 diabetes, maintaining good blood sugar control early and consistently is crucial because high blood sugar creates lasting chemical byproducts (AGEs and OxPs) that damage blood vessels for years, even after glucose levels are normalized. This damage contributes to heart disease risk long-term, highlighting the importance of early intervention and sustained management rather than just recent control.

Bariatric surgery achieves superior long-term weight loss compared to lifestyle interventions, but this comes with complex physiological changes including transient decreases in resting metabolic rate per fat-free mass and alterations in gut peptides like GLP-1 and PYY.

Bariatric surgery is currently the most effective long-term treatment for obesity, achieving ~25% weight loss. However, it works through complex hormonal changes (like increased GLP-1) and metabolic adaptations, not just stomach size reduction. It requires lifelong medical monitoring.

Skeletal muscle transcriptomic profiling, specifically focusing on a core set of 332 insulin-sensitive genes (CORE-IS) and non-coding RNAs, provides a robust molecular signature for metabolic disease that correlates with genetic loci identified by GWAS and responds to clinical interventions.

This research does not offer a direct lifestyle or supplement intervention. Instead, it highlights that current genetic testing (GWAS) is insufficient for predicting metabolic disease risk without functional data. It suggests that future diagnostics may rely on gene expression profiles (transcriptomics) from muscle tissue to accurately assess insulin sensitivity and metabolic health, potentially guiding personalized treatment strategies for type 2 diabetes and obesity.

Cardiovascular polypills (low-dose combinations of BP, lipid, and anti-thrombotic drugs) may serve as a partial exercise mimetic for cardiovascular risk reduction, though they do not fully replicate exercise's protective mechanisms.

If you cannot exercise, a cardiovascular polypill (combining low-dose BP, lipid, and anti-clotting meds) is a viable, evidence-based strategy to reduce cardiovascular risk. It is not a perfect substitute for exercise but offers significant protection with good adherence rates.

Higher baseline expression of caveolin-1 in adipocytes enables greater hypertrophic expansion (fat cell enlargement) in response to caloric overfeeding in healthy humans.

Your body's ability to store fat in your cells (hypertrophy) when you eat more is linked to the levels of a protein called caveolin-1. People with higher levels of this protein tend to get larger fat cells rather than creating new ones. While you cannot directly 'take' caveolin-1, understanding that fat cells are dynamic and responsive to lipid levels (shrinking when mobilized) suggests that metabolic flexibility is key.

GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.

Be aware that GLP-1 medications can slightly increase your risk of gallbladder issues, such as gallstones or inflammation. This risk is higher if you take higher doses or use the medication for a long time. While the absolute risk is low, report any severe abdominal pain to your doctor promptly.

Obesity alters the pharmacokinetics of drugs, affecting absorption, distribution, metabolism, and excretion, which may necessitate dose adjustments for certain medications.

If you have obesity, tell your doctor about all medications you take. Your body may process drugs differently, requiring dose adjustments for safety and effectiveness, especially for drugs metabolized by the liver or kidneys.

Obesity induces chronic low-grade inflammation (LGCI) via adipose tissue hypertrophy, immune cell infiltration (M1 macrophages), and cytokine release (TNF-α, IL-6, IL-1β), which disrupts insulin signaling through JNK and NF-κB pathways, leading to systemic insulin resistance and metabolic dysfunction.

If you have obesity, your body is likely in a state of chronic, low-grade inflammation that actively works against your metabolic health. This isn't just 'being fat'; it's a biological state that disrupts how your body handles insulin and energy. Addressing this inflammation through lifestyle changes (diet, exercise) or medical interventions is crucial for breaking the cycle of metabolic dysfunction.

Tirzepatide slows the rate of eGFR decline in patients with type 2 diabetes, including those with preserved kidney function (eGFR >60 mL/min/1.73 m2) and normoalbuminuria.

Even if your kidney function tests are currently normal, tirzepatide can help protect your kidneys from future decline. Clinical data shows that this medication slows the rate of kidney function loss compared to insulin, regardless of whether you currently have signs of kidney disease. This makes it a valuable preventive tool for long-term kidney health in people with type 2 diabetes.

Oral branched-chain amino acid (BCAA) supplementation provides negligible benefits for athletic performance and body composition in trained athletes, regardless of supplementation duration or dosage.

If you are an athlete, stop spending money on BCAA supplements for performance or muscle gain. The evidence shows they provide negligible benefits over a normal diet. Ensure you are eating enough total protein daily instead. BCAAs might help slightly with muscle soreness after heavy resistance training, but this is not a guaranteed or significant benefit for most people.

Roux-en-Y gastric bypass (RYGB) surgery restores gut hormone balance by elevating postprandial GLP-1 and PYY levels, which contributes to sustained weight loss and improved glucose homeostasis.

For patients who have undergone Roux-en-Y gastric bypass, the surgery works largely by changing how gut hormones signal fullness (GLP-1 and PYY). This hormonal shift helps maintain weight loss and improves blood sugar control long-term. If surgery is not an option, new combination drug therapies aim to replicate this hormonal effect.

Higher circulating levels of specific trans fatty acids (t-16:1n9 and t-18:1) are positively associated with an increased risk of incident type 2 diabetes in older adults, but this association is largely explained by their correlation with de novo lipogenesis (DNL) markers rather than a direct causal effect of the trans fats themselves.

Focus on overall dietary quality rather than fixating solely on trans fats. This study suggests that high levels of certain circulating fatty acids, which are linked to how your body produces its own fats (de novo lipogenesis), are associated with higher diabetes risk. Since dietary self-reports didn't show a clear link, prioritizing whole foods, fiber, and healthy fats (like those in fish and nuts) is likely more effective for diabetes prevention than just avoiding processed foods with trans fats.

Higher long-term circulating levels of de novo lipogenesis-related fatty acids (palmitic acid 16:0, palmitoleic acid 16:1n-7, and oleic acid 18:1n-9) are associated with increased all-cause, cardiovascular, and non-cardiovascular mortality in older adults, whereas higher levels of stearic acid (18:0) are associated with lower mortality risk.

For older adults, high levels of certain fatty acids in the blood (palmitic, palmitoleic, and oleic acids) signal higher long-term mortality risk, while stearic acid signals lower risk. These levels reflect metabolic processes like de novo lipogenesis, often driven by excess carbohydrate and alcohol intake. Focus on metabolic health markers rather than just total fat intake.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) produce a statistically significant but clinically modest reduction in systolic blood pressure (SBP) compared to placebo, with effects ranging from -1.46 to -3.40 mmHg.

GLP-1 medications (like Ozempic or Wegovy) consistently lower systolic blood pressure by a small but measurable amount (1-3 mmHg). This benefit occurs regardless of whether you have diabetes. It is not a substitute for blood pressure medication, but it is a favorable side effect that supports heart health.

GLP-1 receptor agonists generally do not significantly reduce diastolic blood pressure (DBP), with the exception of exenatide.

Do not expect GLP-1 medications to significantly lower your diastolic (bottom number) blood pressure, unless you are taking exenatide. Most GLP-1s primarily affect systolic pressure.

Salivary testosterone and cortisol ratios are inconsistent predictors of strength performance and are not practical for regular training regulation due to high variability between individuals and lack of immediate utility.

Do not rely on blood or saliva tests for daily training decisions. They are expensive, invasive, and inconsistent. Instead, use performance metrics like barbell speed or how hard the set felt (RPE) to guide your training.